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Highlights 
 KEYNOTE-021 evaluated pembrolizumab plus ipilimumab in second-line advanced NSCLC
 Antitumor activity was observed with pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg
 Efficacy in these heavily pretreated patients was similar to historical controls
 This combination dosed every 3 weeks was associated with meaningful toxicity
Abstract 
Objectives: Combination immunotherapy may result in improved antitumor activity compared 
with single-agent treatment. We report results from dose-finding and dose-expansion cohorts of 
the phase 1/2 KEYNOTE-021 study that evaluated combination therapy with anti‒programmed 
death 1 (PD-1) antibody pembrolizumab plus anti‒cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
antibody ipilimumab in patients with previously treated advanced non–small-cell lung cancer 
(NSCLC). 
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Materials and Methods: Eligibility criteria stipulated histologically/cytologically confirmed 
advanced NSCLC and treatment failure on ≥1 prior systemic therapy (platinum-based 
chemotherapy or targeted therapy for patients with EGFR/ALK aberrations). In the dose-finding 
cohort, patients initially received pembrolizumab 10 mg/kg plus ipilimumab 1 or 3 mg/kg once 
every 3 weeks for 4 cycles followed by pembrolizumab 10 mg/kg monotherapy for up to 2 years. 
Based on emerging published data, subsequent patients received pembrolizumab 2 mg/kg plus 
ipilimumab 1 mg/kg. Objective response rate (ORR; primary efficacy endpoint) was assessed per 
RECIST version 1.1 by blinded, independent central review. Phase 2 hypothesis that ORR would 
be greater than the 20% rate for historical controls was evaluated using the exact binomial test. 
Results: Fifty-one patients were enrolled; 71% received ≥2 prior lines of therapy. No dose-limiting 
toxicities occurred at any dose level. Among patients who received pembrolizumab 2 mg/kg plus 
ipilimumab 1 mg/kg (n=44), ORR was 30% (95% CI, 17%–45%), but not statistically significantly 
>20% (P=0.0858). Median progression-free survival in this group was 4.1 (95% CI, 1.4–5.8) 
months; median overall survival was 10.9 (95% CI, 6.1–23.7) months. With pembrolizumab 2 
mg/kg plus ipilimumab 1 mg/kg, incidences of treatment-related adverse events, grade 3–5 
treatment-related adverse events, and immune-mediated adverse events and infusion reactions 
were 64%, 29% and 42%, respectively. 
Conclusions: In patients with heavily pretreated advanced NSCLC, pembrolizumab plus 
ipilimumab showed evidence of antitumor activity, but was associated with meaningful toxicity. 
Keywords: Drug Therapy, Combination; Carcinoma, Non-Small-Cell Lung; pembrolizumab; 
ipilimumab 
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1. Introduction 
Immunotherapy with checkpoint inhibitors has transformed the treatment of advanced non–small-
cell lung cancer (NSCLC) [1]. Immune checkpoint inhibitors have been shown to improve 
outcomes, including overall survival (OS), compared with chemotherapy in both the first- [2] and 
second-line [3-7] settings when administered as monotherapy.  
The humanized monoclonal antibody pembrolizumab blocks the interaction between programmed 
death 1 (PD-1) and its ligands programmed death ligand 1 and 2 (PD-L1, PD-L2) [8]. Binding of 
PD-1 on T cells by PD-L1 on tumor cells suppresses T cell effector functions; treatment with 
pembrolizumab results in reactivation of the antitumor immune response, as evidenced by an 
increase in intratumoral CD8-positive T cells [9]. In the phase 2/3 KEYNOTE-010 study, 
pembrolizumab significantly improved OS and objective response rate (ORR) compared with 
docetaxel in patients with previously treated advanced NSCLC with PD-L1 expression on ≥1% of 
tumor cells (tumor proportion score [TPS] ≥1%) [5]. Compared with standard platinum-based 
chemotherapy, pembrolizumab monotherapy improved progression-free survival (PFS) and OS in 
patients with previously untreated NSCLC of any histology with PD-L1 TPS ≥50% in the 
KEYNOTE-024 study [2] and improved OS in patients with PD-L1 TPS ≥1% in the KEYNOTE-
042 study [10]. In cohort G of the phase 2 KEYNOTE-021 study, pembrolizumab plus pemetrexed 
and carboplatin improved ORR and PFS compared with pemetrexed and carboplatin alone in 
patients with nonsquamous NSCLC, independent of PD-L1 status [11]. Recently, in the phase 3 
KEYNOTE-189 study, pembrolizumab plus pemetrexed-platinum chemotherapy improved OS 
and PFS compared to placebo plus pemetrexed-platinum in patients with previously untreated 
metastatic nonsquamous NSCLC [12]. Similarly, in the phase 3 KEYNOTE-407 study, 
pembrolizumab plus carboplatin-paclitaxel/nab-paclitaxel improved OS and PFS compared with 
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placebo plus carboplatin-paclitaxel/nab-paclitaxel in patients with previously untreated metastatic 
squamous NSCLC [13]. 
Ipilimumab is a humanized monoclonal antibody against cytotoxic T-lymphocyte antigen-4 
(CTLA-4), a molecule expressed on the surface of T cells that negatively regulates interleukin-2 
production as well as T-cell proliferation and survival [14]. Treatment with ipilimumab has been 
associated with clonal expansion of CD8-positive T cells [15]. Ipilimumab has demonstrated 
activity in the treatment of melanoma [16,17], and as first-line therapy in advanced NSCLC when 
combined with anti–PD-1 therapy [18,19]. Notably, although results from a phase 2 study 
suggested a benefit with ipilimumab when used in a phased regimen with carboplatin-paclitaxel 
[20], no benefit was observed in a phase 3 trial evaluating this regimen [21]. 
Combining immunotherapies such as anti-PD-1 and anti-CTLA-4 agents, which target 
complementary pathways in the cancer-immunity cycle, might result in additive or synergistic 
antitumor activity compared with single-agent therapy [22,23]. In support of this hypothesis, the 
combination of nivolumab and ipilimumab has been shown to improve survival compared with 
ipilimumab alone in patients with previously untreated advanced NSCLC (only PFS data reported 
to date) [19] and melanoma albeit with an increased risk of grade 3 or 4 toxicity [24,25]. 
KEYNOTE-021 (ClinicalTrials.gov, NCT02039674) is a multicohort phase 1/2 study evaluating 
pembrolizumab-based combination therapies in patients with NSCLC. We report results for 
cohorts D (dose-finding cohort) and H (dose-expansion cohort), which evaluated pembrolizumab 
plus ipilimumab as second-line therapy for patients with advanced NSCLC. The primary 
objectives of these cohorts were to identify a recommended phase 2 dose for pembrolizumab in 
combination with ipilimumab and to evaluate antitumor activity of the combination.  
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2. Methods 
2.1. Eligibility 
The study populations for cohorts D and H of KEYNOTE-021 consisted of adults with 
histologically or cytologically confirmed stage IIIB/IV NSCLC (any histology) who had 
previously received ≥1 platinum-based chemotherapy or an appropriate targeted therapy and had 
experienced treatment failure; multiple prior lines of treatment were permitted. Eligibility criteria 
also stipulated that patients have ≥1 measurable lesion per Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1 [26], Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 to 1, life expectancy ≥3 months, adequate organ function, and provision of a tumor 
biopsy for assessment of PD-L1 expression. Key exclusion criteria included any previous 
treatment targeting immunoregulatory receptors or mechanisms (eg, PD-1, PD-L1, and CTLA-4), 
receipt of >30 Gy of radiation to the lungs in the previous 6 months, active autoimmune disease 
requiring systemic treatment (ie, disease-modifying agents, corticosteroids, immunosuppressive 
drugs) in the previous 2 years, active interstitial lung disease or history of pneumonitis requiring 
intravenous glucocorticoids, and untreated brain metastases (stable, treated metastases allowed). 
Patients provided written informed consent. The study protocol was approved by an institutional 
review board at each site (protocol number MK-3475-021-03). The study was conducted in 
accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. 
2.2. Study Design 
In both cohorts, patients received four 3-week cycles of pembrolizumab plus ipilimumab, with 
ipilimumab administered ≥30 minutes after pembrolizumab infusion, followed by pembrolizumab 
monotherapy every three weeks (Q3W) for up to 2 years. Cohort D was a dose-finding cohort with 
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a 3+3 design in which dose-limiting toxicities (DLTs) during the first 3-week treatment cycle were 
evaluated in order to determine the recommended phase 2 dose of pembrolizumab in combination 
with ipilimumab. A DLT was defined as a treatment-related grade 3 nonhematologic, 
nonlaboratory toxicity lasting >3 days despite optimal supportive care; grade 4 nonhematologic, 
nonlaboratory toxicity; grade 3/4 nonhematologic laboratory value persisting for >1 week or 
requiring medical intervention or hospitalization; grade 4 hematologic toxicity lasting ≥7 days; 
grade 3/4 febrile neutropenia; thrombocytopenia <25,000/mm3 requiring elective platelet 
transfusion, urgent intervention, or intensive care unit admission; delay in initiating cycle 2 for >2 
weeks due to treatment-related toxicity; or a grade 5 event.  
The first 3 patients enrolled in cohort D received pembrolizumab 10 mg/kg plus ipilimumab 1 
mg/kg. If ≤1 DLT occurred during cycle 1, 3 additional patients were to be enrolled at that dose 
level. If no DLTs occurred, the dose level was escalated and 3 patients were to be enrolled at a 
dose level of pembrolizumab 10 mg/kg plus ipilimumab 3 mg/kg. If ≤1 DLT occurred during cycle 
1 at this dose level, 3 additional patients were to be enrolled.  
Although no DLTs occurred among the first 6 patients enrolled in cohort D, safety concerns 
external to this trial (including treatment-related deaths) were noted in a phase 1 study evaluating 
nivolumab plus ipilimumab in patients with advanced NSCLC [18,27]. This led to a protocol 
amendment stipulating that all subsequent patients enrolled in cohort D receive pembrolizumab 2 
mg/kg plus ipilimumab 1 mg/kg. If ≤1 DLT occurred during cycle 1 at this lower dose, 3 additional 
patients were to be enrolled. If ≤1 of the first 6 patients treated with pembrolizumab 2 mg/kg plus 
ipilimumab 1 mg/kg had DLTs, the dose was to be considered the recommended phase 2 dose and 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on December 18, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
Pembrolizumab Plus Ipilimumab as Second-Line Therapy for Advanced NSCLC 
Page 9 of 34 
6 additional patients would be enrolled to receive this dose. All patients in cohort H (dose 
expansion) received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg. 
Study treatment continued until confirmed disease progression by RECIST version 1.1, intolerable 
toxicity, investigator decision, or withdrawal of consent. Clinically stable patients with radiologic 
evidence of disease progression could continue treatment until progression was confirmed ≥4 
weeks later. Treatment with pembrolizumab was withheld in the event of severe or life-threatening 
treatment-related toxicities. Ipilimumab dosing could be modified as clinically indicated, in 
accordance with the ipilimumab prescribing information. 
The primary objective in part 1 (cohort D) was determination of a recommended phase 2 dose; 
evaluation of antitumor activity per RECIST version 1.1 was a secondary objective. The primary 
objective in part 2 (cohort H) was evaluation of antitumor activity of the combination as assessed 
by the ORR per RECIST version 1.1; evaluation of PFS, OS, and duration of response were 
secondary objectives. 
2.3. Assessments 
Radiographic imaging was performed at baseline, every 6 weeks for the first 18 weeks, every 9 
weeks during the remainder of the first year, and every 12 weeks during the second year. Response 
was assessed per RECIST version 1.1 by blinded, independent central review. Adverse events 
(AEs) and laboratory abnormalities were monitored during the study and graded per National 
Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. At 
baseline, formalin-fixed tumor samples were evaluated for PD-L1 expression from core needle 
biopsies, excisional biopsies, or resected tissue collected at the time of diagnosis of metastatic 
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disease. Assessment was performed at a central laboratory using the PD-L1 IHC 22C3 pharmDx 
assay (Agilent Technologies, Carpinteria, CA). PD-L1 expression was reported as TPS. 
2.4. Statistical Analysis 
Analyses included all patients who received study treatment. Results from cohorts D and H for 
patients who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg were combined for 
analysis, as prespecified in the protocol. The difference between the observed ORR and the 
historical control rate of 20% was evaluated using a one-sided exact binomial test. With 44 
patients, the study had approximately 90% power to detect a 20% difference between the observed 
and historical ORR at =0.05. PFS, OS, and duration of response were estimated using the Kaplan-
Meier method. PFS was defined as the time from start of treatment to the earlier of disease 
progression or death; OS was determined based on the time from start of treatment to death; and 
duration of response was defined as the time from the first documented evidence of objective 
response to the earlier of disease progression or death.  
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3. Results 
 Patients 
Fifty-one patients from 11 sites in the United States were enrolled in cohorts D and H. This 
included 18 patients in cohort D enrolled between February 27, 2014 and January 29, 2015 who 
received pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg (n=3), pembrolizumab 10 mg/kg plus 
ipilimumab 3 mg/kg (n=3), or pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg (n=12). The 
remaining 33 patients were enrolled in cohort H between April 6, 2015 and December 14, 2015 
and received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg. Most patients had ECOG 
performance status of 1, 22% had an EGFR mutation, and 29% had brain metastases. The majority 
of patients (71%) had received ≥2 lines of prior therapy, and 33% had received ≥3 prior therapies 
(Table 1). One patient in the pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg group had an 
original diagnosis of NSCLC that was later discovered to be metastatic melanoma; this patient was 
excluded from efficacy analyses but included in safety analyses. As of the cutoff date (November 
7, 2016), 1 of 6 patients who received pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg 
completed 2 years of treatment; the remaining 5 patients had discontinued (progressive disease, 
n=4; physician decision, n=1). For these 6 patients, median follow-up duration was 20.8 (range, 
6.5–31.6) months, and median number of cycles of pembrolizumab was 9.5 (range, 3–35). Among 
patients who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg (n=45), 1 patient 
completed treatment, 2 were ongoing, and 42 had discontinued (disease progression, n=22; AE, 
n=10; clinical progression, n=8; withdrawal of consent, n=2). Median follow-up duration for these 
patients was 11.3 (range, 0.3–26.9) months, and they received a median of 4 (range, 1–35) cycles 
of pembrolizumab. 
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 Dose-Limiting Toxicities 
No DLTs occurred among patients in either of the 2 pembrolizumab 10 mg/kg ipilimumab dose 
groups. Similarly, no DLTs occurred among the 12 patients who were enrolled after the protocol 
amendment and received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg. Therefore, the 
requirements for dose expansion were met.  
 Efficacy 
Among the 6 patients who received pembrolizumab 10 mg/kg, 3 had partial responses, yielding an 
ORR of 50% (Table 2). Median time to response was 1.4 (range, 1.4–20.7) months, and median 
duration of response had not been reached (range, 8.3 [ongoing] to 28.8 [ongoing]). At the time of 
analysis, 3 patients had died. 
Among patients who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg and were 
included in the efficacy analyses (n=44), 13 had an objective response (1 complete response, 12 
partial responses), and 11 had stable disease as their best response. The ORR was 30% (95% CI, 
17%–45%), which was not significantly greater than the 20% threshold specified in the primary 
hypothesis (P=0.0858). The disease control rate (complete response + partial response + stable 
disease) was 55%. Among patients with a response, median (range) time to response was 2.7 (1.3–
6.2) months, and median duration of response was 10.5 (2.5 [ongoing] to 21.0) months. ORR was 
25% (5/20) in patients with PD-L1 TPS <1%, 39% (7/18) among patients with TPS 1% to 49%, 
and 17% (1/6) in patients with TPS ≥50%. Of 10 patients with EGFR mutations, 1 had an objective 
response (ORR, 10%). ORRs were 38% (5/13) in patients with <2 lines of prior therapy and 26% 
(8/31) in those with ≥2 lines of prior therapy. Best response change from baseline in the sum of 
longest diameters of target lesions is shown in Figure 1. 
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At the time of analysis, 39 patients had died or experienced disease progression; median PFS was 
4.1 (95% CI, 1.4–5.8) months, and the 6-month PFS rate was 32% (95% CI, 19%–46%; Figure 
2A). Twenty-six patients had died; median OS was 10.9 (95% CI, 6.1–23.7) months with a 6-
month OS rate of 67% (95% CI, 51%–79%; Figure 2B). 
 Toxicity 
Among the 6 patients who received pembrolizumab 10 mg/kg, 1 patient who received 
pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg had a treatment-related grade 3 reduction in 
lymphocyte count; there were no other grade 3–5 treatment-related AEs among these patients 
(Table 3). Immune-mediated AEs and infusion reactions (regardless of attribution to study 
treatment or immune relatedness by the investigator) occurred in 2 patients: one patient had grade 
2 hypothyroidism, and a second patient had grade 1 pneumonitis and uveitis (grade 2). 
Among the 45 patients who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg, 44 (98%) 
experienced ≥1 AE, irrespective of relationship to study treatment, with 22 (49%) having grade 3–
5 AEs. Treatment-related AEs occurred in 29/45 patients (64%), with fatigue, hypothyroidism, 
decreased appetite, diarrhea, and pruritus each occurring in >10% of patients (Table 3). Grade 3–
5 treatment-related AEs occurred in 13/45 patients (29%), with colitis being the only event to occur 
in more than one patient (n=2; both grade 3). Three patients had grade 4 treatment-related AEs 
(pancytopenia, large-intestine perforation, and diabetic ketoacidosis), and there was 1 treatment-
related death (pancreatitis occurring during cycle 23). Treatment-related AEs led to 
discontinuation of pembrolizumab and/or ipilimumab in 9 (20%) patients (pancytopenia, 
hyperthyroidism, hypothyroidism, colitis, large intestine perforation, pancreatitis, fatigue, alanine 
aminotransferase increased, aspartate aminotransferase increased, diabetic ketoacidosis, and 
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myasthenia gravis); no individual event resulted in treatment discontinuation in >1 patient. 
Immune-mediated AEs and infusion reactions occurred in 19 (42%) patients; hypothyroidism was 
the only immune-mediated event reported in >10% of patients (Table 3). Eight (18%) patients had 
grade 3–5 immune-mediated AEs and infusion reactions: grade 5 pancreatitis (n=1); grade 4 
diabetic ketoacidosis (n=1); and grade 3 severe skin reactions (n=3), colitis (n=2), adrenal 
insufficiency (n=1), and pneumonitis (n=1). 
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4. Discussion 
In this phase 1/2 study evaluating pembrolizumab plus ipilimumab in patients with previously 
treated NSCLC, more than one-third of whom had received ≥3 lines of prior therapy, we found 
evidence of antitumor activity, but the ORR of 30% with pembrolizumab 2 mg/kg plus ipilimumab 
1 mg/kg did not meet the prespecified endpoint of being significantly greater than 20% (ie, 
superiority over historical control; P=0.0858). Although no DLTs occurred at any of the dose 
levels tested, the combination of pembrolizumab and ipilimumab was associated with meaningful 
toxicity in patients with previously treated advanced NSCLC .  
Safety data external to the current study—including 3 treatment-related deaths among 49 patients 
in an interim analysis of several of the early dose cohorts in the CheckMate 012 study, which 
evaluated nivolumab plus ipilimumab in advanced NSCLC [18,27]—led to a decision to evaluate 
the efficacy of pembrolizumab plus ipilimumab at doses of pembrolizumab 2 mg/kg and 
ipilimumab 1 mg/kg. At this dose level, the combination of pembrolizumab plus ipilimumab was 
associated with meaningful toxicity that was greater than that observed with pembrolizumab 
monotherapy in previously treated advanced NSCLC [5]. In the current study, 20% discontinued 
treatment due to a treatment-related AE and 29% experienced 1 or more treatment-related grade 
3–5 AEs, including 3 who experienced grade 4 events and 1 patient who died. In the KEYNOTE-
010 study, which evaluated pembrolizumab monotherapy in previously treated advanced NSCLC, 
percentages of patients who discontinued due to treatment-related AEs (4% and 5% with 
pembrolizumab 2 mg/kg and 10 mg/kg, respectively) and percentages with treatment-related grade 
3–5 AEs (13% and 16%, respectively) were comparatively lower [5]. Whereas, in the KEYNOTE-
024 study, which evaluated pembrolizumab monotherapy in treatment-naive patients with 
advanced NSCLC and PD-L1 TPS ≥50%, the rate of treatment-related AEs was higher compared 
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to the current study (73% vs 64% in patients who received pembrolizumab 2 mg/kg plus 
ipilimumab 1 mg/kg), but the rate of discontinuation from those events was lower (7% vs 20%) 
[2]. In addition, in patients with melanoma, nivolumab plus ipilimumab combination regimens 
have demonstrated increased rates of AEs [24,25], some of which can be difficult to diagnose and 
manage [28,29]. It is possible that the high rate of discontinuation in our study may be due to 
similar challenges with immune-mediated AEs, and that increased experience with such 
combination regimens may result in improved strategies for toxicity management. Additionally, 
ipilimumab was dosed Q3W in our study, a dosing schedule that was not found suitable for further 
clinical development in the CheckMate 012 study [18]. The nature of observed treatment-related 
AEs in the current study (fatigue, hypothyroidism, decreased appetite, diarrhea, and pruritus 
occurred most frequently) matched what would be anticipated given the immune mechanism of 
action of both agents, and the safety profile was generally consistent with that reported in studies 
evaluating nivolumab plus ipilimumab in advanced NSCLC [18,19] and melanoma [24,30]. 
Although the prespecified threshold for clinical improvement was not met, the ORR of 30% in this 
heavily pretreated group of patients, the majority of whom had received ≥2 lines of prior therapy, 
compares favorably with the 18% rate reported for pembrolizumab 2 mg/kg monotherapy in the 
KEYNOTE-010 study, which enrolled previously treated patients with PD-L1 TPS ≥1%, most of 
whom had received 1 prior line of therapy for advanced disease [5]. In addition, a higher proportion 
of patients had brain metastases and were positive for EGFR mutation at baseline in the current 
study compared with KEYNOTE-010 [5] and there were only 4 patients with squamous NSCLC 
enrolled, both of which could have potentially influenced the study outcome. PD-(L)1 inhibition 
has been shown to lead to similar or worse outcomes compared to chemotherapy in patients with 
EGFR mutations [31-33]. The limited number of patients with squamous histology in this study 
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precludes histology-based assessment of outcomes with this combination. In CheckMate 227, 
improvements in PFS were observed with the combination of nivolumab plus ipilimumab versus 
chemotherapy in treatment-naive patients with TMB ≥10 mutations/megabase with either 
squamous (HR, 0.63; 95% CI, 0.39–1.04) or nonsquamous NSCLC (HR, 0.55; 95% CI; 0.38–0.80) 
[19]. However, these data are not conclusive, given that the 95% confidence intervals for the HR 
for squamous histology contained 1. 
Notably, almost 50% of patients in the current study who were evaluable for efficacy at the 
pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg dose level had PD-L1 TPS <1%, which has 
previously been shown to be associated with lower ORR with pembrolizumab monotherapy in the 
KEYNOTE-001 study [34]. Although there was little evidence of an influence of PD-L1 
expression on the ORR in the current study, interpretation of this finding is limited by the relatively 
small number of patients enrolled. Nonetheless, with median follow-up of 11.3 months, median 
PFS and OS were 4.1 and 10.9 months, respectively. These outcomes were similar to those 
reported with pembrolizumab 2 mg/kg monotherapy after a similar follow-up duration in 
previously treated patients with PD-L1–positive advanced NSCLC in the KEYNOTE-010 study 
(PFS, 3.9 months; OS, 10.4 months, respectively) [5]. 
Other studies have evaluated anti–PD-1/anti–PD-L1 plus anti–CTLA-4 combinations in patients 
with advanced NSCLC. Though unacceptable toxicity was observed in earlier cohorts in the open-
label, phase 1, multicohort study CheckMate 012, which evaluated nivolumab plus ipilimumab in 
previously untreated advanced NSCLC, these cohorts received ipilimumab dosing Q3W. With the 
combination of nivolumab 3 mg/kg Q2W plus ipilimumab 1 mg/kg at dosing intervals of Q6W or 
Q12W, manageable toxicity was observed after a median follow-up of approximately 1 year [18]. 
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When pooled across both dose schedules, ORR appeared to be greater with nivolumab plus 
ipilimumab than with nivolumab monotherapy (43% vs 23%); albeit this trial was not randomized 
across the combination and monotherapy cohorts. In contrast to findings from our study, there 
appeared to be an association between PD-L1 expression and ORR in CheckMate 012 (PD-L1 
<1%, 18%; PD-L1 ≥1%, 57%), although it is noteworthy that the PD-L1 assay and antibody used 
to determine TPS were different than those used in our study [18]. 
More recently, the open-label, multipart, phase 3 CheckMate 227 trial compared outcomes in 
treatment-naive patients with advanced NSCLC who received nivolumab 3 mg/kg Q2W plus 
ipilimumab 1 mg/kg Q6W compared with platinum doublet chemotherapy [19]. In part 1 of this 
study, the coprimary endpoint of median (95% CI) PFS among patients with high tumor mutational 
burden (TMB; ≥10 mutations/megabase) was longer in those who received nivolumab plus 
ipilimumab (7.2 months [5.5–13.2]) versus chemotherapy (5.5 months [4.4–5.8]) with a hazard 
ratio (HR) of 0.58 (97.5% CI, 0.41–0.81; P<0.001). However, similar results were not observed 
with nivolumab monotherapy in patients with TMB ≥13 mutations/megabase and PD-L1 ≥1% (HR 
for nivolumab monotherapy versus chemotherapy, 0.95; 97.5% CI, 0.61–1.48; P=0.78). Of note, 
TMB was not assessed among our patients. In the overall population, irrespective of TMB or PD-
L1 expression, median PFS was 4.9 (95% CI, 4.1–5.6) months with nivolumab plus ipilimumab, 
which was similar to the results from our current study, versus 5.5 (95% CI, 4.6–5.6) months with 
chemotherapy [19]. 
In a phase 1b dose-escalation study in patients with previously untreated NSCLC, the combination 
of the anti–PD-L1 antibody durvalumab and the anti–CTLA-4 antibody tremelimumab had a 
manageable tolerability profile and was associated with antitumor activity [35]. The maximum 
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tolerated dose was durvalumab 15 mg/kg Q4W plus tremelimumab 3 mg/kg once Q4W 
administered for 6 weeks, followed by once Q12W. Notably, responses occurred irrespective of 
tumor PD-L1 expression. It has recently been reported that in the MYSTIC trial, which compares 
this combination with platinum-based chemotherapy in patients with previously untreated NSCLC 
[36], the coprimary endpoint of improved PFS in patients with PD-L1 TPS ≥25% was not met; 
evaluation of the coprimary endpoint of OS is ongoing [37].  
In conclusion, the combination of pembrolizumab plus ipilimumab had antitumor activity in 
heavily pretreated patients but was associated with meaningful toxicity. At present, 
pembrolizumab 200 mg Q3W plus ipilimumab 1 mg/kg once Q6W is being evaluated in treatment-
naive patients with advanced NSCLC with PD-L1 TPS ≥50% in the randomized, placebo-
controlled phase 3 KEYNOTE-598 study (ClinicalTrials.gov, NCT03302234), which was 
designed based on the experience from our current study [38]. KEYNOTE-598 will evaluate a 
different dosing schedule (ipilimumab Q6W rather than Q3W) specifically in patients with PD-L1 
TPS ≥50% [38]. Additionally, ongoing phase 3 trials are evaluating nivolumab plus ipilimumab 
[39] and durvalumab plus tremelimumab [40] in patients with previously untreated NSCLC. These 
studies will provide further information on the efficacy and safety of anti–PD-1/anti–PD-L1 plus 
anti–CTLA-4 therapy in patients with advanced NSCLC. 
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Figure Legends 
Figure 1.  Change from baseline in the sum of longest diameters of target lesions in patients 
who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg in cohorts D and 
H. One patient who had an original diagnosis of NSCLC but was later determined 
to have metastatic melanoma was excluded from efficacy analyses but included in 
safety analyses; 12 additional patients are excluded from this figure because of 
missing target lesion information. *Patients with PD-L1 TPS ≥1%. PD-L1 = 
programmed death ligand 1; TPS = tumor proportion score.  
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Figure 2. Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival 
among patients who received pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg. 
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Table 1. Baseline Demographic and Disease Characteristics 
 Pembrolizumab 10 mg/kg + 
ipilimumab 
(N = 6)a 
Pembrolizumab 2 mg/kg + 
ipilimumab 1 mg/kg 
(N = 45)b 
Median (range) age, y 64 (54–75) 61 (28–79) 
Sex, n (%)   
Male 3 (50) 23 (51) 
Female 3 (50) 22 (49) 
ECOG performance status, n (%)   
0 1 (17) 11 (24) 
1 5 (83) 34 (76) 
Tumor histology, n (%)   
Adenocarcinoma 4 (67) 37 (82) 
Squamous 0 4 (9) 
NSCLC not otherwise specified 2 (33) 4 (9) 
Smoking status, n (%)   
Current or former smoker 4 (67) 34 (76) 
Never smoker 2 (33) 10 (22) 
Missing 0 1 (2) 
Brain metastasis, n (%) 1 (17) 14 (31) 
PD-L1 TPS, n (%)   
<1% 1 (17) 21 (47) 
1%–49% 1 (17) 18 (40) 
≥50% 4 (67) 6 (13) 
Prior lines of systemic therapy, n 
(%) 
  
1 2 (33) 13 (29) 
2 4 (67) 15 (33) 
≥3 0 17 (38) 
EGFR mutation status, n (%)   
Wild type 5 (83) 33 (73) 
Mutant 1 (17) 10 (22) 
Undeterminedc 0 2 (4) 
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 Pembrolizumab 10 mg/kg + 
ipilimumab 
(N = 6)a 
Pembrolizumab 2 mg/kg + 
ipilimumab 1 mg/kg 
(N = 45)b 
 
ALK translocation status, n (%) 
Wild type 5 (83) 41 (91) 
Mutant 0 1 (2) 
Undeterminedc 1 (17) 3 (7) 
ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-cell lung cancer; PD-L1, programmed 
death ligand 1; TPS, tumor proportion ccore. 
aThree patients received pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg, and 3 patients received 
pembrolizumab 10 mg/kg plus ipilimumab 3 mg/kg. 
bOne patient in the pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg group had an original diagnosis of 
NSCLC that was later discovered to be metastatic melanoma and is excluded from efficacy analyses but 
included in safety analyses. 
cDetermination of EGFR mutation or ALK translocation was not required in patients with squamous 
histology; determination of ALK status was not required for patients with EGFR mutations. Determination 
of EGFR status was not required for patients with known KRAS mutations. 
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Table 2. Summary of Response to Treatment 
 Pembrolizumab 10 mg/kg + 
ipilimumab 
(N = 6)a 
Pembrolizumab 2 mg/kg + 
ipilimumab 1 mg/kg 
(N = 44)b 
Best overall response, n (%)   
Complete response 0 1 (2) 
Partial response 3 (50) 12 (27) 
Stable disease 2 (33) 11 (25) 
Progressive disease 1 (17) 13 (30) 
Not evaluable 0 7 (16) 
Objective response rate, % (95% 
CI) 
50 (12–88) 30 (17–45) 
P value (for objective response 
rate >20%)c 
– 0.0858 
Objective response rate by PD-L1 
TPS status, n/N (%)d 
  
PD-L1 TPS <1% – 5/20 (25) 
PD-L1 TPS 1%–49% – 7/18 (39) 
PD-L1 TPS ≥50% – 1/6 (17) 
Time to response, 
median (range), mo 
1.4 (1.4–20.7) 2.7 (1.3–6.2) 
Duration of response, 
median (range), mo 
Not reached (8.3+ to 28.8+) 10.5 (2.5+ to 21.0) 
PD-L1, programmed death ligand 1; TPS, tumor proportion score. 
aThree patients received pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg, and 3 patients received 
pembrolizumab 10 mg/kg plus ipilimumab 3 mg/kg. 
bOne patient in the pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg group had an original diagnosis of 
NSCLC that was later discovered to be metastatic melanoma and is excluded from efficacy analyses but 
included in safety analyses. 
cOne-sided P value based on exact binomial distribution for testing the null hypothesis that the objective 
response rate was ≤20% vs the alternative hypothesis that objective response rate was >20%. 
dThe small number of patients in the pembrolizumab 10 mg/kg + ipilimumab group precludes meaningful 
analysis of ORR data by PD-L1 TPS status. 
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Table 3. Incidence of Adverse Events 
 Pembrolizumab 10 mg/kg + 
ipilimumab 
(N = 6)a 
Pembrolizumab 2 mg/kg + 
ipilimumab 1 mg/kg 
(N = 45)b 
Treatment-related AEs, n (%)   
Any grade 6 (100) 29 (64) 
Grade 3–5 AE 1 (17) 13 (29) 
Led to discontinuation 1 (17) 9 (20) 
Led to death 0 1 (2) 
Treatment-related AEs occurring in 
≥3 patients in the pembrolizumab 
2 mg/kg + ipilimumab 1 mg/kg 
group, n (%) 
Any grade Grade 3–5 Any grade Grade 3–5 
Fatigue 3 (50) 0 12 (27) 1 (2) 
Hypothyroidism 1 (17) 0 10 (22) 0 
Decreased appetite 2 (33) 0 5 (11) 0 
Diarrhea 2 (33) 0 5 (11) 1 (2) 
Pruritus 1 (17) 0 5 (11) 0 
Arthralgia 1 (17) 0 3 (7) 0 
Myalgia 1 (17) 0 3 (7) 0 
Rash 1 (17) 0 3 (7) 0 
Headache 0 0 3 (7) 0 
Nausea 0 0 3 (7) 0 
Mucosal inflammation 0 0 3 (7) 0 
Pneumonitis 0 0 3 (7) 1 (2) 
Thyroiditis 0  0 3 (7) 0 
Immune mediated AEs and infusion 
reactions, n (%) 
Any grade Grade 3–5 Any grade Grade 3–5 
Hypothyroidism 1 (17) 0 11 (24) 0 
Pneumonitis 1 (17) 0 3 (7) 1 (2) 
Uveitis 1 (17) 0 0 0 
Thyroiditis 0 0 4 (9) 0 
Severe skin reactions 0 0 3 (7) 3 (7) 
Colitis 0 0 2 (4) 2 (4) 
Hyperthyroidism 0 0 2 (4) 0 
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 Pembrolizumab 10 mg/kg + 
ipilimumab 
(N = 6)a 
Pembrolizumab 2 mg/kg + 
ipilimumab 1 mg/kg 
(N = 45)b 
Adrenal insufficiency 0 0 1 (2) 1 (2) 
Myasthenic syndrome 0 0 1 (2) 0 
Pancreatitis 0 0 1 (2) 1 (2) 
Type 1 diabetes mellitus 0 0 1 (2) 1 (2) 
AE, adverse event. 
aThree patients received pembrolizumab 10 mg/kg plus ipilimumab 1 mg/kg, and 3 patients received 
pembrolizumab 10 mg/kg plus ipilimumab 3 mg/kg. 
bOne patient in the pembrolizumab 2 mg/kg plus ipilimumab 1 mg/kg group had an original diagnosis of 
NSCLC that was later discovered to be metastatic melanoma and is excluded from efficacy analyses but 
included in safety analyses. 
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